Evaluation of immunization status in patients with cerebral palsy: a multicenter CP-VACC study.


Journal

European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 09 03 2021
accepted: 21 07 2021
revised: 24 05 2021
pubmed: 7 8 2021
medline: 19 1 2022
entrez: 6 8 2021
Statut: ppublish

Résumé

Children with chronic neurological diseases, including cerebral palsy (CP), are especially susceptible to vaccine-preventable infections and face an increased risk of severe respiratory infections and decompensation of their disease. This study aims to examine age-appropriate immunization status and related factors in the CP population of our country. This cross-sectional prospective multicentered survey study included 18 pediatric neurology clinics around Turkey, wherein outpatient children with CP were included in the study. Data on patient and CP characteristics, concomitant disorders, vaccination status included in the National Immunization Program (NIP), administration, and influenza vaccine recommendation were collected at a single visit. A total of 1194 patients were enrolled. Regarding immunization records, the most frequently administrated and schedule completed vaccines were BCG (90.8%), hepatitis B (88.9%), and oral poliovirus vaccine (88.5%). MMR was administered to 77.3%, and DTaP-IPV-HiB was administered to 60.5% of patients. For the pneumococcal vaccines, 54.1% of children received PCV in the scope of the NIP, and 15.2% of children were not fully vaccinated for their age. The influenza vaccine was administered only to 3.4% of the patients at any time and was never recommended to 1122 parents (93.9%). In the patients with severe (grades 4 and 5) motor dysfunction, the frequency of incomplete/none vaccination of hepatitis B, BCG, DTaP-IPV-HiB, OPV, and MMR was statistically more common than mild to moderate (grades 1-3) motor dysfunction (p = 0.003, p < 0.001, p < 0.001, p < 0.00, and p < 0.001, respectively). Physicians' influenza vaccine recommendation was higher in the severe motor dysfunction group, and the difference was statistically significant (p = 0.029).Conclusion: Children with CP had lower immunization rates and incomplete immunization programs. Clinicians must ensure children with CP receive the same preventative health measures as healthy children, including vaccines. What is Known: • Health authorities have defined chronic neurological diseases as high-risk conditions for influenza and pneumococcal infections, and they recommend vaccines against these infections. • Children with CP have a high risk of incomplete and delayed immunization, a significant concern given to their increased healthcare needs and vulnerability to infectious diseases. What is New: • Influenza vaccination was recommended for patients hospitalized due to pneumonia at a higher rate, and patients were administered influenza vaccine more commonly. • Children with CP who had higher levels of motor dysfunction (levels 4 and 5) were more likely to be overdue immunizations.

Identifiants

pubmed: 34355277
doi: 10.1007/s00431-021-04219-4
pii: 10.1007/s00431-021-04219-4
doi:

Substances chimiques

Diphtheria-Tetanus-Pertussis Vaccine 0
Haemophilus Vaccines 0
Poliovirus Vaccine, Inactivated 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-391

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Havers F, Fry AM, Chen J et al (2016) Hospitalizations attributable to respiratory ınfections among children with neurologic disorders. J Pediatr 170:135–141. https://doi.org/10.1016/j.jpeds.2015.11.030
doi: 10.1016/j.jpeds.2015.11.030 pubmed: 26687576
Campbell AJP, Grohskopf LA (2018) Updates on ınfluenza vaccination in children. Infect Dis Clin North Am 32(1):75–89
doi: 10.1016/j.idc.2017.11.005
Pandolfi E, Graziani MC, Ieraci R et al (2008) A comparison of populations vaccinated in a public service and in a private hospital setting in the same area. BMC Public Health 8:278
doi: 10.1186/1471-2458-8-278
Tillmann BU, Tillmann HC, Heininger U et al (2005) Acceptance and timeliness of standard vaccination in children with chronic neurological deficits in north-western Switzerland. Eur J Pediatr 164(5):320–325
doi: 10.1007/s00431-005-1627-x
Dinleyici M, Carman KB, Kilic O et al (2018) The immunization status of children with chronic neurological disease and serological assessment of vaccine-preventable diseases. Hum Vaccin Immunother 14(8):1970–1976
doi: 10.1080/21645515.2018.1460986
Gasparini R, Panatto D, Lai PL et al (2015) The “urban myth” of the association between neurological disorders and vaccinations. J Prev Med Hyg 56(1):1–8
Rosenbaum P, Paneth N, Leviton A et al (2007) A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol 49:8–14
Palisano R, Rosenbaum P, Walter S et al (1997) Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39:214–223
doi: 10.1111/j.1469-8749.1997.tb07414.x
Tervo RC, Taylor B (1982) Vaccinations and the physically handicapped child. CMAJ 127:475–477
Ministry of Health (2019) Health Statistics Yearbook 2018. https://dosyasb.saglik.gov.tr/Eklenti/36164,siy2018en2pdf.pdf . Accessed 12 May 2021
Greenwood VJ, Crawford NW, Walstab JE et al (2013) Immunisation coverage in children with cerebral palsy compared with the general population. J Paediatr Child Health 49(2):137–141
doi: 10.1111/jpc.12097
Blair E, Langdon K, McIntyre S et al (2019) Survival and mortality in cerebral palsy: observations to the sixth decade from a data linkage study of a total population register and National Death Index. BMC Neurol 19(1):111
doi: 10.1186/s12883-019-1343-1
WHO (2020) Turkey: WHO and UNICEF estimates of immunization coverage: 2019 revision. https://www.who.int/immunization/monitoring_surveillance/data/tur.pdf . Accessed 11 May 2020
CDC (2020) Prevention and control of seasonal ınfluenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States 2020–21 Summary of Recommendations. https://www.cdc.gov/flu/professionals/acip/summary/summary-recommendations.htm. Accessed 11 May 2020
Keren R, Zaoutis TE, Bridges CB et al (2005) Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. JAMA 294(17):2188–2194
doi: 10.1001/jama.294.17.2188
Wong KK, Jain S, Blanton L et al (2013) Influenza-associated pediatric deaths in the United States 2004–2012. Pediatrics 132(5):796–804
doi: 10.1542/peds.2013-1493
Gill PJ, Ashdown HF, Wang K et al (2015) Identification of children at risk of influenza-related complications in primary and ambulatory care: a systematic review and meta-analysis. Lancet Respir Med 3(2):139–149
doi: 10.1016/S2213-2600(14)70252-8
Pandolfi E, Carloni E, Marino MG et al (2012) Immunization coverage and timeliness of vaccination in Italian children with chronic diseases. Vaccine 30(34):5172–5178
doi: 10.1016/j.vaccine.2011.02.099
Havers FP, Fry AM, Peacock G et al (2018) Influenza vaccination coverage in children with neurologic disorders and their siblings July 2006 to June 2014. Pediatr Infect Dis J 37(8):814–816
doi: 10.1097/INF.0000000000001929
Bax M, Goldstein M, Rosenbaum P et al (2005) Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 47(8):571–576
doi: 10.1017/S001216220500112X
Serdaroğlu A, Cansu A, Ozkan S et al (2006) Prevalence of cerebral palsy in Turkish children between the ages of 2 and 16 years. Dev Med Child Neurol 48(6):413–416
doi: 10.1111/j.1469-8749.2006.tb01288.x

Auteurs

Sema Bozkaya-Yilmaz (S)

Department of Pediatric Neurology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey. semabozkayayilmaz@gmail.com.

Eda Karadag-Oncel (E)

Department of Pediatric Infectious Diseases, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.

Nihal Olgac-Dundar (N)

Department of Pediatric Neurology, Faculty of Medicine, Katip Çelebi University, Izmir, Turkey. nodundar@gmail.com.

Pinar Gencpinar (P)

Department of Pediatric Neurology, Faculty of Medicine, Katip Çelebi University, Izmir, Turkey.

Berrak Sarioglu (B)

Department of Pediatric Neurology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.

Pinar Arican (P)

Department of Pediatric Neurology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.

Atilla Ersen (A)

Department of Pediatric Neurology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.

Dilek Yilmaz-Ciftdoğan (D)

Department of Pediatric Infectious Diseases, Faculty of Medicine, Katip Celebi University, Izmir, Turkey.

Merve Feyza Yuksel (MF)

Department of Pediatric Neurology, Faculty of Medicine, Ankara University, Ankara, Turkey.

Omer Bektas (O)

Department of Pediatric Neurology, Faculty of Medicine, Ankara University, Ankara, Turkey.

Serap Teber (S)

Department of Pediatric Neurology, Faculty of Medicine, Ankara University, Ankara, Turkey.

Betul Kilic (B)

Department of Pediatric Neurology, Faculty of Medicine, Medipol University, Istanbul, Turkey.

Mustafa Calik (M)

Department of Pediatric Neurology, Faculty of Medicine, Harran University, Sanlıurfa, Turkey.

Meryem Karaca (M)

Department of Pediatric Metabolism, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Mehmet Canpolat (M)

Department of Pediatric Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Sefer Kumandas (S)

Department of Pediatric Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Huseyin Per (H)

Department of Pediatric Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Hakan Gumus (H)

Department of Pediatric Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Selcan Ozturk (S)

Department of Pediatric Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.

Cetin Okuyaz (C)

Department of Pediatric Neurology, Faculty of Medicine, Mersin University, Mersin, Turkey.

Mustafa Komur (M)

Department of Pediatric Neurology, Faculty of Medicine, Mersin University, Mersin, Turkey.

Rojan Ipek (R)

Department of Pediatric Neurology, Faculty of Medicine, Mersin University, Mersin, Turkey.

Pınar Ozbudak (P)

Department of Pediatric Neurology, Faculty of Medicine, Gazi University, Ankara, Turkey.

Ebru Arhan (E)

Department of Pediatric Neurology, Faculty of Medicine, Gazi University, Ankara, Turkey.

Hulya Ince (H)

Department of Pediatric Neurology, Samsun Medical Park Hospital, Samsun, Turkey.

Gurkan Gurbuz (G)

Department of Pediatric Neurology, Faculty of Medicine, Namik Kemal University, Tekirdag, Turkey.

Gulen Gul Mert (GG)

Department of Pediatric Neurology, Faculty of Medicine, Cukurova University, Adana, Turkey.

Neslihan Ozcan (N)

Department of Pediatric Neurology, Faculty of Medicine, Cukurova University, Adana, Turkey.

Akgun Olmez Turker (AO)

Department of Pediatric Neurology, Private Clinic, Denizli, Turkey.

Hande Gazeteci-Tekin (H)

Department of Pediatric Neurology, Faculty of Medicine, Bakircay University, Izmir, Turkey.

Serkan Kırık (S)

Department of Pediatric Neurology, Faculty of Medicine, Firat University, Elazig, Turkey.

Ceren Günbey (C)

Department of Pediatric Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Kürşat Bora Çarman (KB)

Department of Pediatric Neurology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.

Coşkun Yarar (C)

Department of Pediatric Neurology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.

Dilek Çavuşoğlu (D)

Department of Pediatric Neurology, Faculty of Medicine, Afyon Kocatepe University, Afyon, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH